Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Ultragenyx Pharmaceutical Inc. < Previous 1 2 Next > Ultragenyx to Participate in Investor Conferences in September August 29, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) August 21, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update August 01, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update July 25, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium July 24, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) July 19, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program July 17, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 20, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants June 13, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants June 12, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) June 12, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) June 11, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers MREO RARE Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference June 04, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) May 30, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 17, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference May 07, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update May 02, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease April 30, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) April 30, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update April 25, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 19, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 April 15, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome April 12, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting April 12, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) March 22, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Participate at Investor Conferences in March February 27, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) February 23, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update February 15, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update February 08, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) February 06, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.